galantamine has been researched along with glutamic acid in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Albuquerque, EX; Alkondon, M; Aracava, Y; Eisenberg, HM; Maelicke, A; Pereira, EF; Santos, MD | 1 |
| Kanki, R; Kihara, T; Maelicke, A; Nakamizo, T; Sawada, H; Shimohama, S; Yamashita, H | 1 |
| Geerts, H | 1 |
| Akaike, A; Kanki, R; Kawamata, J; Kihara, T; Nakamizo, T; Sawada, H; Shimohama, S; Yamashita, H | 1 |
| Aisen, PS | 1 |
| Akaike, A; Katsuki, H; Kume, T; Sugimoto, H; Sugimoto, M; Takada, Y; Yamaguchi, T; Yonezawa, A | 1 |
| Geerts, H; Grossberg, GT | 1 |
| Akaike, A; Fujii, T; Katsuki, H; Kume, T; Niidome, T; Okabe, S; Sugimoto, H; Sugimoto, M; Takada-Takatori, Y | 1 |
| Shimohama, S | 2 |
| Albuquerque, EX; Bruno, JP; Pellicciari, R; Pereira, EF; Schwarcz, R; Wu, HQ | 1 |
| Bartha, R; Borrie, MJ; Penner, J; Rupsingh, R; Smith, M; Wells, JL | 1 |
| Alexander, KS; Bruno, JP; Schwarcz, R; Wu, HQ | 1 |
| Alexander, KS; Bruno, JP; Pershing, ML; Pocivavsek, A; Schwarcz, R; Wu, HQ | 1 |
| Antonelli, T; Beggiato, S; Ferraro, L; Fuxe, K; Schwarcz, R; Tanganelli, S; Tomasini, MC | 1 |
| Antonelli, T; Beggiato, S; Ferraro, L; Fuxe, K; Schwarcz, R; Tanganelli, S | 1 |
| Emad Aboulhoda, B; Gamal, M; Magdy, S; Mohammed, HS; Rashed, L; Samir, NF; Sharawy, N | 1 |
5 review(s) available for galantamine and glutamic acid
| Article | Year |
|---|---|
Indicators of neuroprotection with galantamine.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Galantamine; Glutamic Acid; Humans; In Vitro Techniques; Indicators and Reagents; Models, Biological; Neuroprotective Agents; Treatment Outcome | 2005 |
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Management; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Glutamic Acid; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2005 |
Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Glutamic Acid; Humans; Memantine; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic | 2006 |
[Treatment of Alzheimer's disease: status quo and future considerations].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Behavioral Symptoms; Choline; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Design; Galantamine; Glutamic Acid; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Risk Factors; Rivastigmine | 2008 |
Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Drug Synergism; Galantamine; Glutamic Acid; Motor Neurons; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylinositol 3-Kinases; Rats; Receptors, Nicotinic; Rotenone; Signal Transduction; Spinal Cord | 2009 |
1 trial(s) available for galantamine and glutamic acid
| Article | Year |
|---|---|
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cholinesterase Inhibitors; Creatine; Female; Galantamine; Glutamic Acid; Hippocampus; Humans; Inositol; Magnetic Resonance Spectroscopy; Male; Mental Status Schedule; Neuropsychological Tests; Regression Analysis | 2010 |
11 other study(ies) available for galantamine and glutamic acid
| Article | Year |
|---|---|
The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.
Topics: Action Potentials; Allosteric Regulation; Animals; Antibodies, Monoclonal; Central Nervous System; Cholinesterases; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Postsynaptic Potentials; Galantamine; gamma-Aminobutyric Acid; Glutamic Acid; Hippocampus; Humans; In Vitro Techniques; Neurons; Nicotine; Nootropic Agents; Rats; Rats, Sprague-Dawley; Receptors, Cholinergic; Receptors, Glutamate; Synaptic Transmission; Time Factors | 2002 |
Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity.
Topics: Amyloid beta-Peptides; Animals; Cell Survival; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Interactions; Galantamine; Glutamic Acid; Neurons; Neuroprotective Agents; Rats; Receptors, Nicotinic | 2004 |
Stimulation of nicotinic acetylcholine receptors protects motor neurons.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Bungarotoxins; Cell Death; Cell Survival; Cells, Cultured; Cholinesterase Inhibitors; Dihydro-beta-Erythroidine; Fetus; Galantamine; Glutamic Acid; Immunohistochemistry; Motor Neurons; Nicotine; Nicotinic Agonists; Rats; Rats, Wistar; Receptors, Nicotinic; Spinal Cord | 2005 |
Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons.
Topics: Animals; Calcium; Cells, Cultured; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Administration Schedule; Galantamine; Glutamic Acid; Immunoblotting; Indans; Neurons; Piperidines; Protein Subunits; Rats; Rats, Wistar; Receptors, Nicotinic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Up-Regulation | 2005 |
Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity.
Topics: Animals; Cell Survival; Cells, Cultured; Cerebral Cortex; Cholinesterase Inhibitors; Cysteine; Dihydro-beta-Erythroidine; Dose-Response Relationship, Drug; Fetus; Galantamine; Glutamic Acid; Ionomycin; Ionophores; Mecamylamine; Neuroprotective Agents; Nicotinic Antagonists; Nitric Oxide Donors; Rats; Rats, Wistar; S-Nitrosothiols; Tacrine | 2006 |
The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Cholinesterase Inhibitors; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Extracellular Fluid; Galantamine; Glutamic Acid; Kynurenic Acid; Kynurenine; Male; Microdialysis; Nicotinic Antagonists; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Schizophrenia | 2010 |
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Cognition; Cognition Disorders; Disease Models, Animal; Galantamine; Glutamic Acid; Kynurenic Acid; Kynurenine; Male; Nootropic Agents; Prefrontal Cortex; Rats; Rats, Wistar; Receptors, Nicotinic; Schizophrenia | 2012 |
Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine.
Topics: Animals; Attention; Brain; Cognition; Female; Galantamine; Glutamic Acid; Kynurenic Acid; Kynurenine; Male; Nootropic Agents; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Set, Psychology | 2013 |
Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Cholinergic Agonists; Cholinergic Antagonists; Corpus Striatum; Extracellular Space; Galantamine; gamma-Aminobutyric Acid; Glutamic Acid; Kynurenic Acid; Male; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Schiff Bases | 2013 |
Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha7 Nicotinic Acetylcholine Receptor; Animals; Central Nervous System Agents; Cholinergic Agents; Excitatory Amino Acid Antagonists; Extracellular Space; Galantamine; gamma-Aminobutyric Acid; Glutamic Acid; Kynurenic Acid; Male; Microdialysis; Prefrontal Cortex; Rats, Sprague-Dawley; Receptors, Glycine; Schiff Bases | 2014 |
IκB kinase inhibition remodeled connexins, pannexin-1, and excitatory amino-acid transporters expressions to promote neuroprotection of galantamine and morphine.
Topics: Animals; Anti-Inflammatory Agents; Brain; Connexins; Disease Models, Animal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Galantamine; Glutamic Acid; I-kappa B Kinase; Lipopolysaccharides; Male; Morphine; Nerve Tissue Proteins; Neurodegenerative Diseases; Neuroglia; Neurons; Neuroprotection; Neuroprotective Agents; Nitriles; Rats, Sprague-Dawley; Signal Transduction; Sulfones | 2021 |